At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Apr 27, 2026 at 07:00 ET
Sionna Therapeutics announced completion of patient enrollment in its Phase 2a PreciSION CF trial evaluating SION-719, a first-in-class NBD1 stabilizer, in cystic fibrosis patients on Trikafta. Topline data is expected in summer 2026, marking a key clinical catalyst for the company's novel CFTR-targeting approach.
- Completed enrollment in Phase 2a PreciSION CF trial for SION-719, a first-in-class NBD1 stabilizer.
- Trial evaluates SION-719 added to Trikafta in F508del-homozygous CF patients using a crossover design.
- Primary endpoints include safety, pharmacokinetics, and change in sweat chloride levels (a biomarker of CFTR function).
- Topline data expected in summer 2026, representing a near-term clinical readout.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access